TIM-3 is also highly expressed in peripheral blood CD3+ T-cells from patients with DLBCL and is related to tumor stage and responses to conventional chemotherapy [46, 47]. This evidence concerns the gene HAVCR2 and diffuse large B-cell lymphoma.